Cargando…

Thiazide diuretics and the rate of disease progression in autosomal dominant polycystic kidney disease: an observational study

BACKGROUND: In autosomal dominant polycystic kidney disease (ADPKD), hypertension is prevalent and cardiovascular events are the main cause of death. Thiazide diuretics are often prescribed as second-line antihypertensives, on top of renin–angiotensin–aldosterone system (RAAS) blockade. There is a c...

Descripción completa

Detalles Bibliográficos
Autores principales: Kramers, Bart J, Koorevaar, Iris W, De Boer, Rudolf, Hoorn, Ewout J, Pena, Michelle J, Gansevoort, Ron T, Meijer, Esther
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8476080/
https://www.ncbi.nlm.nih.gov/pubmed/33150452
http://dx.doi.org/10.1093/ndt/gfaa150
_version_ 1784575529031041024
author Kramers, Bart J
Koorevaar, Iris W
De Boer, Rudolf
Hoorn, Ewout J
Pena, Michelle J
Gansevoort, Ron T
Meijer, Esther
author_facet Kramers, Bart J
Koorevaar, Iris W
De Boer, Rudolf
Hoorn, Ewout J
Pena, Michelle J
Gansevoort, Ron T
Meijer, Esther
author_sort Kramers, Bart J
collection PubMed
description BACKGROUND: In autosomal dominant polycystic kidney disease (ADPKD), hypertension is prevalent and cardiovascular events are the main cause of death. Thiazide diuretics are often prescribed as second-line antihypertensives, on top of renin–angiotensin–aldosterone system (RAAS) blockade. There is a concern, however, that diuretics may increase vasopressin concentration and RAAS activity, thereby worsening disease progression in ADPKD. We aimed to investigate the validity of these suggestions. METHODS: We analysed an observational cohort of 533 ADPKD patients. Plasma copeptin (surrogate for vasopressin), aldosterone and renin were measured by enzyme-linked immunosorbent assay and radioimmunoassay, respectively. Linear mixed models were used to assess the association of thiazide use with estimated glomerular filtration rate (eGFR) decline and Cox proportional hazards models for the association with the composite kidney endpoint of incident end-stage kidney disease, 40% eGFR decline or death. RESULTS: A total of 23% of participants (n = 125) used thiazide diuretics at baseline. Compared with non-users, thiazide users were older, a larger proportion was male, they had lower eGFRs and similar blood pressure under more antihypertensives. Plasma copeptin was higher, but this difference disappeared after adjustment for age and sex. Both renin and aldosterone were higher in thiazide users. There was no difference between thiazide users and non-users in the rate of eGFR decline {difference −0.35 mL/min/1.73 m(2) per year [95% confidence interval (CI) −0.83 to –0.14], P = 0.2} during 3.9 years of follow-up (interquartile range 2.5–4.9). This did not change after adjustment for potential confounders [difference final model: 0.08 mL/min/1.73 m(2) per year [95% CI −0.46 to –0.62], P = 0.8). In the crude model, thiazide use was associated with a higher incidence of the composite kidney endpoint [hazard ratio (HR) 1.53 (95% CI 1.05–2.23), P = 0.03]. However, this association lost significance after adjustment for age and sex and remained unassociated after adjustment for additional confounders [final model: HR 0.80 (95% CI 0.50–1.29), P = 0.4]. CONCLUSIONS: These data do not show that thiazide diuretics have a detrimental effect on the rate of disease progression in ADPKD and suggest that these drugs can be prescribed as second-line antihypertensives.
format Online
Article
Text
id pubmed-8476080
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-84760802021-09-28 Thiazide diuretics and the rate of disease progression in autosomal dominant polycystic kidney disease: an observational study Kramers, Bart J Koorevaar, Iris W De Boer, Rudolf Hoorn, Ewout J Pena, Michelle J Gansevoort, Ron T Meijer, Esther Nephrol Dial Transplant Original Articles BACKGROUND: In autosomal dominant polycystic kidney disease (ADPKD), hypertension is prevalent and cardiovascular events are the main cause of death. Thiazide diuretics are often prescribed as second-line antihypertensives, on top of renin–angiotensin–aldosterone system (RAAS) blockade. There is a concern, however, that diuretics may increase vasopressin concentration and RAAS activity, thereby worsening disease progression in ADPKD. We aimed to investigate the validity of these suggestions. METHODS: We analysed an observational cohort of 533 ADPKD patients. Plasma copeptin (surrogate for vasopressin), aldosterone and renin were measured by enzyme-linked immunosorbent assay and radioimmunoassay, respectively. Linear mixed models were used to assess the association of thiazide use with estimated glomerular filtration rate (eGFR) decline and Cox proportional hazards models for the association with the composite kidney endpoint of incident end-stage kidney disease, 40% eGFR decline or death. RESULTS: A total of 23% of participants (n = 125) used thiazide diuretics at baseline. Compared with non-users, thiazide users were older, a larger proportion was male, they had lower eGFRs and similar blood pressure under more antihypertensives. Plasma copeptin was higher, but this difference disappeared after adjustment for age and sex. Both renin and aldosterone were higher in thiazide users. There was no difference between thiazide users and non-users in the rate of eGFR decline {difference −0.35 mL/min/1.73 m(2) per year [95% confidence interval (CI) −0.83 to –0.14], P = 0.2} during 3.9 years of follow-up (interquartile range 2.5–4.9). This did not change after adjustment for potential confounders [difference final model: 0.08 mL/min/1.73 m(2) per year [95% CI −0.46 to –0.62], P = 0.8). In the crude model, thiazide use was associated with a higher incidence of the composite kidney endpoint [hazard ratio (HR) 1.53 (95% CI 1.05–2.23), P = 0.03]. However, this association lost significance after adjustment for age and sex and remained unassociated after adjustment for additional confounders [final model: HR 0.80 (95% CI 0.50–1.29), P = 0.4]. CONCLUSIONS: These data do not show that thiazide diuretics have a detrimental effect on the rate of disease progression in ADPKD and suggest that these drugs can be prescribed as second-line antihypertensives. Oxford University Press 2020-11-05 /pmc/articles/PMC8476080/ /pubmed/33150452 http://dx.doi.org/10.1093/ndt/gfaa150 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Articles
Kramers, Bart J
Koorevaar, Iris W
De Boer, Rudolf
Hoorn, Ewout J
Pena, Michelle J
Gansevoort, Ron T
Meijer, Esther
Thiazide diuretics and the rate of disease progression in autosomal dominant polycystic kidney disease: an observational study
title Thiazide diuretics and the rate of disease progression in autosomal dominant polycystic kidney disease: an observational study
title_full Thiazide diuretics and the rate of disease progression in autosomal dominant polycystic kidney disease: an observational study
title_fullStr Thiazide diuretics and the rate of disease progression in autosomal dominant polycystic kidney disease: an observational study
title_full_unstemmed Thiazide diuretics and the rate of disease progression in autosomal dominant polycystic kidney disease: an observational study
title_short Thiazide diuretics and the rate of disease progression in autosomal dominant polycystic kidney disease: an observational study
title_sort thiazide diuretics and the rate of disease progression in autosomal dominant polycystic kidney disease: an observational study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8476080/
https://www.ncbi.nlm.nih.gov/pubmed/33150452
http://dx.doi.org/10.1093/ndt/gfaa150
work_keys_str_mv AT kramersbartj thiazidediureticsandtherateofdiseaseprogressioninautosomaldominantpolycystickidneydiseaseanobservationalstudy
AT koorevaaririsw thiazidediureticsandtherateofdiseaseprogressioninautosomaldominantpolycystickidneydiseaseanobservationalstudy
AT deboerrudolf thiazidediureticsandtherateofdiseaseprogressioninautosomaldominantpolycystickidneydiseaseanobservationalstudy
AT hoornewoutj thiazidediureticsandtherateofdiseaseprogressioninautosomaldominantpolycystickidneydiseaseanobservationalstudy
AT penamichellej thiazidediureticsandtherateofdiseaseprogressioninautosomaldominantpolycystickidneydiseaseanobservationalstudy
AT gansevoortront thiazidediureticsandtherateofdiseaseprogressioninautosomaldominantpolycystickidneydiseaseanobservationalstudy
AT meijeresther thiazidediureticsandtherateofdiseaseprogressioninautosomaldominantpolycystickidneydiseaseanobservationalstudy
AT thiazidediureticsandtherateofdiseaseprogressioninautosomaldominantpolycystickidneydiseaseanobservationalstudy